Abstract

Gait is impaired in musculoskeletal conditions, such as knee arthropathy. Gait analysis is used in clinical practice to inform diagnosis and to monitor disease progression or intervention response. However, clinical gait analysis relies on subjective visual observation of walking, as objective gait analysis has not been possible within clinical settings due to the expensive equipment, large-scale facilities, and highly trained staff required. Relatively low-cost wearable digital insoles may offer a solution to these challenges. In this work, we demonstrate how a digital insole measuring osteoarthritis-specific gait signatures yields similar results to the clinical gait-lab standard. To achieve this, we constructed a machine learning model, trained on force plate data collected in participants with knee arthropathy and controls. This model was highly predictive of force plate data from a validation set (area under the receiver operating characteristics curve [auROC] = 0.86; area under the precision-recall curve [auPR] = 0.90) and of a separate, independent digital insole dataset containing control and knee osteoarthritis subjects (auROC = 0.83; auPR = 0.86). After showing that digital insole derived gait characteristics are comparable to traditional gait measurements, we next showed that a single stride of raw sensor time series data could be accurately assigned to each subject, highlighting that individuals using digital insoles can be identified by their gait characteristics. This work provides a framework for a promising alternative to traditional clinical gait analysis methods, adds to the growing body of knowledge regarding wearable technology analytical pipelines, and supports clinical development of at-home gait assessments, with the potential to improve the ease, frequency, and depth of patient monitoring.

Data availability

Anonymized data and computer code to reproduce all figures will be made available as supplementary files to this manuscript. All relevant demographic and clinical information, all vGRF, derived gait characteristics, and raw sensor time series data, will be provided, in addition to R and Python scripts used to perform the analysis. Additionally, this information will be uploaded to a Regeneron GitHub account here: https://github.com/regeneron-mpds. This data will be made fully available prior to final publication of this manuscript. The GaitRec dataset is available online here: https://www.nature.com/articles/s41597-020-0481-z

Article and author information

Author details

  1. Matthew F Wipperman

    Precision Medicine, Regeneron, Tarrytown, United States
    For correspondence
    matthew.wipperman@regeneron.com
    Competing interests
    Matthew F Wipperman, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1436-3366
  2. Allen Z Lin

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Allen Z Lin, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  3. Kaitlyn M Gayvert

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Kaitlyn M Gayvert, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  4. Benjamin Lahner

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Benjamin Lahner, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  5. Selin Somersan-Karakaya

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Selin Somersan-Karakaya, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  6. Xuefang Wu

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Xuefang Wu, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  7. Joseph Im

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Joseph Im, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  8. Minji Lee

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Minji Lee, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  9. Bharatkumar Koyani

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Bharatkumar Koyani, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  10. Ian Setliff

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Ian Setliff, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  11. Malika Thakur

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Malika Thakur, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  12. Daoyu Duan

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Daoyu Duan, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  13. Aurora Breazna

    Biostatistics and Data Management, Regeneron, Tarrytown, United States
    Competing interests
    Aurora Breazna, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  14. Fang Wang

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Fang Wang, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  15. Wei Keat Lim

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Wei Keat Lim, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6226-2570
  16. Gabor Halasz

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Gabor Halasz, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  17. Jacek Urbanek

    Biostatistics and Data Management, Regeneron, Tarrytown, United States
    Competing interests
    Jacek Urbanek, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  18. Yamini Patel

    General Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Yamini Patel, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  19. Gurinder S Atwal

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Gurinder S Atwal, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  20. Jennifer D Hamilton

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Jennifer D Hamilton, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  21. Samuel Stuart

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Samuel Stuart, Employee and stockholder of Regeneron Pharmaceuticals, Inc..
  22. Oren Levy

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Oren Levy, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  23. Andreja Avbersek

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Andreja Avbersek, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  24. Rinol Alaj

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    For correspondence
    rinol.alaj@regeneron.com
    Competing interests
    Rinol Alaj, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  25. Sara C Hamon

    Precision Medicine, Regeneron, Tarrytown, United States
    For correspondence
    sara.hamon@regeneron.com
    Competing interests
    Sara C Hamon, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  26. Olivier Harari

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    For correspondence
    olivier.harari@regeneron.com
    Competing interests
    Olivier Harari, Employee and shareholder of Regeneron Pharmaceuticals, Inc..

Funding

Regeneron Pharmaceuticals (N/A)

  • Matthew F Wipperman
  • Allen Z Lin
  • Kaitlyn M Gayvert
  • Benjamin Lahner
  • Selin Somersan-Karakaya
  • Xuefang Wu
  • Joseph Im
  • Minji Lee
  • Bharatkumar Koyani
  • Ian Setliff
  • Malika Thakur
  • Daoyu Duan
  • Aurora Breazna
  • Fang Wang
  • Wei Keat Lim
  • Gabor Halasz
  • Jacek Urbanek
  • Yamini Patel
  • Gurinder S Atwal
  • Jennifer D Hamilton
  • Oren Levy
  • Andreja Avbersek
  • Rinol Alaj
  • Sara C Hamon
  • Olivier Harari

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: For the pilot study, participants were recruited internally within the Regeneron facility located in Tarrytown, NY, USA, and were provided written informed consent prior to participation. The study was considered exempt research under the Common Rule (45 CFR Sec 46.104). The R5069-OA-1849 study protocol received Institutional Review Board and ethics committee approvals from Moldova Medicines and Medical Device Agency and National Ethics Committee for Moldova, and the Western Institutional Review Board.

Copyright

© 2024, Wipperman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 843
    views
  • 129
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthew F Wipperman
  2. Allen Z Lin
  3. Kaitlyn M Gayvert
  4. Benjamin Lahner
  5. Selin Somersan-Karakaya
  6. Xuefang Wu
  7. Joseph Im
  8. Minji Lee
  9. Bharatkumar Koyani
  10. Ian Setliff
  11. Malika Thakur
  12. Daoyu Duan
  13. Aurora Breazna
  14. Fang Wang
  15. Wei Keat Lim
  16. Gabor Halasz
  17. Jacek Urbanek
  18. Yamini Patel
  19. Gurinder S Atwal
  20. Jennifer D Hamilton
  21. Samuel Stuart
  22. Oren Levy
  23. Andreja Avbersek
  24. Rinol Alaj
  25. Sara C Hamon
  26. Olivier Harari
(2024)
Digital wearable insole-based identification of knee arthropathies and gait signatures using machine learning
eLife 13:e86132.
https://doi.org/10.7554/eLife.86132

Share this article

https://doi.org/10.7554/eLife.86132

Further reading

    1. Medicine
    Jeong-Oh Shin, Jong-Bin Lee ... Jin-Woo Kim
    Research Article

    This study investigates the effects of two parathyroid hormone (PTH) analogs, rhPTH(1-34) and dimeric R25CPTH(1-34), on bone regeneration and osseointegration in a postmenopausal osteoporosis model using beagle dogs. Twelve osteoporotic female beagles were subjected to implant surgeries and assigned to one of three groups: control, rhPTH(1-34), or dimeric R25CPTH(1-34). Bone regeneration and osseointegration were evaluated after 10 weeks using micro-computed tomographic (micro-CT), histological analyses, and serum biochemical assays. Results showed that the rhPTH(1-34) group demonstrated superior improvements in bone mineral density, trabecular architecture, and osseointegration compared to controls, while the dimeric R25CPTH(1-34) group exhibited similar, though slightly less pronounced, anabolic effects. Histological and TRAP assays indicated both PTH analogs significantly enhanced bone regeneration, especially in artificially created bone defects. The findings suggest that both rhPTH(1-34) and dimeric R25CPTH(1-34) hold potential as therapeutic agents for promoting bone regeneration and improving osseointegration around implants in osteoporotic conditions, with implications for their use in bone-related pathologies and reconstructive surgeries.

    1. Medicine
    2. Neuroscience
    Sophie Leclercq, Hany Ahmed ... Nathalie Delzenne
    Research Article

    Background:

    Alcohol use disorder (AUD) is a global health problem with limited therapeutic options. The biochemical mechanisms that lead to this disorder are not yet fully understood, and in this respect, metabolomics represents a promising approach to decipher metabolic events related to AUD. The plasma metabolome contains a plethora of bioactive molecules that reflects the functional changes in host metabolism but also the impact of the gut microbiome and nutritional habits.

    Methods:

    In this study, we investigated the impact of severe AUD (sAUD), and of a 3-week period of alcohol abstinence, on the blood metabolome (non-targeted LC-MS metabolomics analysis) in 96 sAUD patients hospitalized for alcohol withdrawal.

    Results:

    We found that the plasma levels of different lipids ((lyso)phosphatidylcholines, long-chain fatty acids), short-chain fatty acids (i.e. 3-hydroxyvaleric acid) and bile acids were altered in sAUD patients. In addition, several microbial metabolites, including indole-3-propionic acid, p-cresol sulfate, hippuric acid, pyrocatechol sulfate, and metabolites belonging to xanthine class (paraxanthine, theobromine and theophylline) were sensitive to alcohol exposure and alcohol withdrawal. 3-Hydroxyvaleric acid, caffeine metabolites (theobromine, paraxanthine, and theophylline) and microbial metabolites (hippuric acid and pyrocatechol sulfate) were correlated with anxiety, depression and alcohol craving. Metabolomics analysis in postmortem samples of frontal cortex and cerebrospinal fluid of those consuming a high level of alcohol revealed that those metabolites can be found also in brain tissue.

    Conclusions:

    Our data allow the identification of neuroactive metabolites, from interactions between food components and microbiota, which may represent new targets arising in the management of neuropsychiatric diseases such as sAUD.

    Funding:

    Gut2Behave project was initiated from ERA-NET NEURON network (Joint Transnational Call 2019) and was financed by Academy of Finland, French National Research Agency (ANR-19-NEUR-0003-03) and the Fonds de la Recherche Scientifique (FRS-FNRS; PINT-MULTI R.8013.19, Belgium). Metabolomics analysis of the TSDS samples was supported by grant from the Finnish Foundation for Alcohol Studies.